SFMG Wealth Advisors’s Edgewise Therapeutics EWTX Stock Holding History

SFMG Wealth Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$315K	Hold	10,000	–	–	0.02%	244
2025 Q4	$248K	Hold	10,000	–	–	0.02%	265
2025 Q3	$162K	Hold	10,000	–	–	0.01%	289
2025 Q2	$131K	Hold	10,000	–	–	0.01%	268
2025 Q1	$220K	Hold	10,000	–	–	0.02%	247
2024 Q4	$267K	Hold	10,000	–	–	0.02%	217
2024 Q3	$267K	Hold	10,000	–	–	0.02%	213
2024 Q2	$180K	Hold	10,000	–	–	0.02%	248
2024 Q1	$182K	Hold	10,000	–	–	0.02%	257
2023 Q4	$109K	Hold	10,000	–	–	0.01%	260
2023 Q3	$57.3K	Hold	10,000	–	–	0.01%	243
2023 Q2	$77.5K	Hold	10,000	–	–	0.01%	242
2023 Q1	$66.7K	Hold	10,000	–	–	0.01%	250
2022 Q4	$89.4K	Hold	10,000	–	–	0.01%	243
2022 Q3	$107K	Sell	10,000 -100	-1%	-$1.01K	0.01%	234
2022 Q2	$80K	Hold	10,100	–	–	0.01%	256
2022 Q1	$98K	Buy	+10,100	New	+$130K	0.01%	283

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SFMG Wealth Advisors's EWTX Position: Q1 2026 in Review

SFMG Wealth Advisors held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 10,000 shares worth $315K. The position accounts for 0.02% of the portfolio, ranked #244.

SFMG Wealth Advisors first reported a position in EWTX in Q1 2022 and has held it in 17 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

SFMG Wealth Advisors held 10,000 shares of Edgewise Therapeutics worth $315K as of Q1 2026.
SFMG Wealth Advisors left its Edgewise Therapeutics share count unchanged in Q1 2026.
Edgewise Therapeutics made up 0.02% of SFMG Wealth Advisors's portfolio in Q1 2026, its #244 holding.
SFMG Wealth Advisors first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 17 quarters since.
214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on SFMG Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.